Ofatumumab

BATCH NUMBER: To be announced

537,00 €

Minimum order quantity: 6

Therapeutic Ofatumumab monoclonal antibody from the original Kesimpta® commercial drug

Drug Aliquots On Demand

  • Commercial drug sourced in the EU
  • Delivery within 2-4 weeks​*
  • Buffer: original drug buffer​
  • Quantity: minimum order quantity required​

*Subject to availability and market fluctuations.

Request For Quotation

Product specifications:​

  • Product Concentration 50 mg/mL
  • Volume per vial 20 µL
  • Quantity per vial 1 mg
  • Batch Number to be announced
  • Storage Temperature 2-8 °C / -80 °C
Our products are for research use only. The “therapeutic expiration date” implies expiry date for patient adminstration and is not applicable to the shelf life of the aliquot. Aliquot storage at -86°C ensures fully functional molecules even after the mentioned expiry date

Product Information:

Evidentic offers repackaged finished pharmaceutical products (e.g RMP/RLD). We refer to the repackaged RMP/RLD products synonymously as drug aliquots or aRMP, or short: aliquots.

We offer batches of original drug aliquots in low-binding Eppendorf tubes for research use only. We provide licence-free drug aliquots with long, short or even “negative shelf life” by storing the products at recommended temperatures (either 2-8°C or -80°C) and ensuring fully functional molecules for research purposes.

As ‘raw material’ for the production of drug aliquots, Evidentic sources RMP from the European (EU) market. As a licensed pharmaceutical wholesaler, Evidentic is committed to Good Distribution Practice (GDP) compliance with respect to the procurement, storage and shipment of RMP.
Drug aliquots are manufactured by repackaging RMP in a qualified laboratory. The aliquotation process is performed under a quality and manufacturing agreement between Evidentic and the contract manufacturer. Repackaging of RMP includes the following steps: opening the secondary and primary RMP containers and transferring the specified volumes of RMP into an Eppendorf 0.5 ml low-binding (or similar) tube. If the RMP is a lyophilized powder and not a highly concentrated solution, reconstitute the RMP according to the original manufacturer’s instructions and then aliquot as a highly concentrated solution.
For identification purposes, drug aliquots are labeled with the date of aliquoting, the original lot number of the RMP, the original expiration date of the RMP, the name of the active ingredient (INN), and a unique identification code.
Immediately after aliquoting, drug aliquots are stored at either 2-8 °C or -86 °C for long-term storage. All drug aliquots stored at 2-8 °C are transferred to -86 °C at least two weeks before the expiration date of the original RLD/RMP is reached. Further quality or functional testing are not performed on the drug aliquots.  

Target

Class of molecule

Isotype

Host cells

Murine cell line (NS0)

Prepared from

Kesimpta®

Therapeutic Area

Therapeutic Indications

Mechanism of Action (MoA)

Ofatumumab is a fully human anti-CD20 monoclonal immunoglobulin G1 (IgG1) antibody. The CD20 molecule is a transmembrane phosphoprotein expressed on B lymphocytes from the pre-B to mature B lymphocyte stage. The CD20 molecule is also expressed on a small fraction of activated T cells. The binding of ofatumumab to CD20 induces lysis of CD20+ B cells primarily through complement-dependent cytotoxicity (CDC) and, to a lesser extent, through antibody-dependent cell-mediated cytotoxicity (ADCC). Ofatumumab has also been shown to induce cell lysis in both high and low CD20 expressing cells. CD20-expressing T cells are also depleted by ofatumumab.

Pharmacotherapeutic group​​

Selective immunosuppressants

List of Excipients​

L-arginine
Sodium acetate trihydrate
Sodium chloride
Polysorbate 80
Disodium edetate dihydrate
Hydrochloric acid (for pH adjustment)
Water for injections

Not looking for Ofatumumab?

Search our therapeutic molecules product database

Evidentic GmbH
Martin-Buber-Str. 10
14163 Berlin

+49 (0) 30 959 99 8831
info@evidentic.com

Cookie Preferences

Linkedin Youtube Facebook Twitter Instagram